Role of Fluoxetine + Olanzapine combination therapy to manage Treatment-Resistant Depression
Starting on:
Oct 31, 2024
Ending on:
Oct 31, 2024
Moderator(s):
Dr. Stacy Njani
Psychiatry Resident, University of Nairobi
Venue:
KPA Monthly CME Webinar
Max Credits:
3 Points

Provider:
Kenya Psychiatrists Association
Claim Points

Role of Fluoxetine + Olanzapine combination therapy to manage Treatment-Resistant Depression

Starting on:
Oct 31, 2024
Ending on:
Oct 31, 2024
Venue:
KPA Monthly CME Webinar

Description

Kenya Psychiatric Association, in collaboration with NabiQasim Industries Pvt Ltd, hosted an insightful webinar on the use of Fluoxetine and Olanzapine combination therapy in managing treatment-resistant depression. This session brought together leading experts in psychiatry to discuss the efficacy, clinical considerations, and outcomes associated with this combination treatment approach.

Objectives

Overview of treatment-resistant depression and challenges in management Mechanism of action and benefits of the Fluoxetine + Olanzapine combination Patient case studies and evidence-based outcomes Practical guidelines for clinicians This session was accredited with 3 CPD Points and is ideal for psychiatrists, psychologists, and mental health professionals interested in advancing their knowledge of combination therapies in psychiatry.

Presenters

  1. Dr. Catherine Syengo
    Consultant Psychiatrist
    Mathari National Teaching and Referral Hospital

  2. Dr. Raza Rahman
    Meritorious Professor & Chairman
    Psychiatry at Dow University of Health Sciences

Search For CPD Activity